NCT06295302招募中2 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Study to Explore the Efficacy, Safety, and Pharmacokinetic Profile of HWH486 in Adults With Chronic Spontaneous Urticaria(CSU)
Hubei Biological Medicine Industrial Technology Institute Co., Ltd.1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2023年12月13日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Change in Urticaria Activity Score (UAS) over a 7-day period (UAS7)
研究概览
简要总结
This is a multicenter, randomized, double-bind and placebo-controlled phase IIa dose-finding study to assess the safety and efficacy of HWH486 in adults with chronic spontaneous urticaria (CSU). In addition, the pharmacokinetic characteristics will also be investigated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18, ≤70 years old;
- •Participants with chronic spontaneous urticaria (CSU) at the time of randomization as defined by the following: presence of itch and hives for ≥ 6 consecutive weeks prior to screening, despite second generation H1-antihistamine during this period; Urticaria Activity Score (UAS7) (range 0-42) ≥16, Hives Severity Score (HSS7) (range 0-21) ≥ 6 and Itch Severity Score (ISS7) (range 0-21) ≥ 6 during 7 consecutive days prior to randomization; CSU duration ≥6 months prior to screening (defined as the onset of CSU as determined by the investigator based on all available supporting documentation).
- •Willing and able to complete the Urticaria Participant Daily eDiary (UPDD) for the duration of the study;
- •Willing to take background medication and emergency medication according to the study protocol.
- •Written informed consent signed voluntarily by the patient or their legal representatives.
排除标准
- •Previous use of HWH486 or other Bruton's tyrosine kinase(BTK) inhibitors;
- •Participants having a predominant or sole trigger of their chronic urticaria (chronic inducible urticaria);
- •Any other skin disease associated with chronic itching that might influence in the investigator's opinion the study evaluations and results, e.g. atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis
- •With symptoms or signs of progressive or uncontrolled kidney, liver, blood, gastrointestinal, endocrine, lung, heart, neurological, psychiatric, or brain disease, or with a history of gastrointestinal bleeding that is associated with a significant risk of bleeding or coagulopathy, or is clinically significant (such as requiring hospitalization or blood transfusion), or with other chronic medical conditions that are not eligible for participation in this clinical trial, or having a history of malignancy, other than non-metastatic basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of the cervix with appropriate treatment and no signs of recurrence;
- •Clinically important laboratory test indicators are abnormal, including: abnormal blood routine: hemoglobin (Hb) < 100g/L, or white blood cell count (WBC) < 3.5×10^9/L; Abnormal liver function: aspartate aminotransferase (AST) ≥1.5×ULN, or alanyl aminotransferase (ALT) ≥1.5×ULN, or total bilirubin (TBIL) ≥1.5×ULN; Abnormal renal function: creatinine (Cr) ≥1×ULN; any other laboratory test indicators that researchers think may affect the evaluation of test results;
- •Active and uncontrolled viral and bacterial infections at the time of screening, such as human immunodeficiency virus(HIV), hepatitis B virus(HBV), hepatitis C virus (HCV), syphilis, tuberculosis test results, or if there are any clinical symptoms of bacterial, viral, parasitic or fungal infection requiring treatment;
- •Pregnant or breastfeeding women; having pregnancy plans during the clinical trial and within 1 month after the last dose, and do not want to take medically accepted reliable contraceptive methods;
- •History of allergy to any investigational therapeutic drug or its excipients;
- •History or evidence of alcohol or drug abuse within the six months prior to randomization;
- •Use of other immunosuppressive drugs, including but not limited to hydroxychloroquine, methotrexate, cyclosporin A, cyclophosphamide, tacrolimus, mycophenolate, tripterygium, and compound glycyrrhizin, within 30 days or 5 half-lives (whichever is older) prior to screening;
- •The investigator determines that the subjects have any conditions that make them unfit to participate in the experiment (such as weak health, poor compliance, etc.).
研究组 & 干预措施
HWH486
Experimental
干预措施: HWH486 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Urticaria Activity Score (UAS) over a 7-day period (UAS7)
时间窗: Baseline, Week 4
Weekly Urticaria Activity Score (UAS7; range 0-42; higher scores reflect greater disease activity)
次要结局
- Change in Hive Severity Score (HSS) over a 7-day period (HSS7)(Baseline to Week 4)
- Change in Itch Severity Score (ISS) over a 7-day period (ISS7)(Baseline to Week 4)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional DyspepsiaFunctional DyspepsiaNCT02567578Yuhan Corporation12
终止
2 期
Phase 2 Dose-finding IMU-838 for Ulcerative ColitisUlcerative ColitisNCT03341962Immunic AG263
已完成
2 期
This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistaminesChronic Spontaneous UrticariaNCT03926611Novartis Pharmaceuticals311
已完成
2 期
Phase II Study of Hemay005 in Patients With Active Ankylosing SpondylitisActive Ankylosing SpondylitisNCT05407246Tianjin Hemay Pharmaceutical Co., Ltd90
已完成
2 期
A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic ArthritisPsoriatic ArthritisNCT04713072ACELYRIN Inc.129